According to a press release issued July 5, Lupin Pharmaceuticals has received FDA approval to market a generic form of the prescription drug Lyrica® (Pregabalin Capsules). Lupin Pharmaceuticals, based in Baltimore, is the 5th largest generic drug marketer in the US, and is a subsidiary of Mumbai-based Lupin Ltd.
The capsules, available in 25, 50, 75, 100, 150, 200, 225 and 300mg, “are the AB-rated* generic equivalent of Lyrica® capsules, indicated for neuropathic pain associated with diabetic peripheral neuropathy, post herpetic neuralgia, adjunctive therapy for adult patients with partial onset seizures and fibromyalgia.”
Stay tuned for information on when where and how (and at what price, of course) this pharmaceutical product will be made available in the US and elsewhere. (Lyrica® sales reached $1.8 billion in the US alone for the 12 months ending March 2012. and $3.4 billion worldwide in 2011.)
* According to the FDA, “AB-rated drugs are drugs that meet the necessary bioequivalence standards established by the Food and Drug Administration (FDA). A generic drug is considered bioequivalent to a brand-name drug if it contains the same active pharmaceutical ingredient as the branded drug, and if there is no significant difference in the formulation, quality, and effectiveness of the two drugs.”